



## Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference

November 10, 2022

DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies London Healthcare Conference on Thursday, November 17 at 2:40 p.m. GMT / 9:40 a.m. ET.

A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel's Investor Relations website, [investors.avadel.com](https://investors.avadel.com), for 90 days following the conference.

### About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, LUMRYZ™, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. For more information, please visit [www.avadel.com](https://www.avadel.com).

### Investor Contact:

Courtney Turiano  
Stern Investor Relations, Inc.  
[Courtney.Turiano@sternir.com](mailto:Courtney.Turiano@sternir.com)  
(212) 698-8687

### Media Contact:

Gabriella Greig  
Real Chemistry  
[ggreig@realchemistry.com](mailto:ggreig@realchemistry.com)  
(203) 249-2688



Source: Avadel Pharmaceuticals plc